Threshold Pharmaceuticals Company Profile - May 15, 2011

Document Sample
Threshold Pharmaceuticals Company Profile - May 15, 2011 Powered By Docstoc
					Company Fundamentals\Company Profile

   A Wright Investors' Service Research Report:

   Threshold Pharmaceuticals, Inc.
                                                                                       440 Wheelers Farms Road
                                                                                       Milford, CT 06461 U.S.A.


  COMPANY PROFILE
  Figures in U.S. Dollars

                                 Wright Quality Rating:DCNN                                 Key Data

   Threshold Pharmaceuticals, Inc (Threshold) is a biotechnology company focused on         Ticker:
   the discovery and development of drugs targeting the microenvironment of solid           THLD
   tumors as treatments for patients living with cancer. Its product candidates are
   designed to focus on the hypoxic microenvironment of tumors either by selective          2008 Sales:
   toxin activation in the case of its hypoxia activated prodrug (HAP) program, including
                                                                                            1,440,000
   TH-302, or utilizing the consequences of increased uptake of glucose in cancer cells
   relative to most normal cells. The Company's product candidate 2-deoxyglucose
   (2DG) and glufosfamide share certain structural characteristics with glucose but act     Major Industry:
   instead as chemotherapeutic toxins when taken up by a cell.                              Drugs, Cosmetics & Health
                                                                                            Care
                         Stock Chart                                 Officers
                                                              Chief Executive Officer
                                                                Dr. Harold E. Selick        Sub Industry:
                                                                                            Ethical Drug Manufacturers

                                                                                            Country:
                                                                                            United States

                                                                                            Currency:
                                                                                            U.S. Dollars

                                                                                            Fiscal Year Ends:
                                                                                            December

                                                                                            Employees
                                                                                            36

                                                                                            Exchanges:
                                                                                            NAS
               Stock Price (5/6/2011): 1.88
                Recent stock performance                                                    Share Type:
                    1 Week      -9.2%
                                                                                            Common
                    4 Weeks      3.3%
                    13 Weeks     8.0%
                    52 Weeks    18.2%                                                       Market Capitalization:
                                                                                            91,736,692
                      Earnings / Dividends (as of 12/31/2010)
                                             Earn
				
DOCUMENT INFO
Description: Threshold Pharmaceuticals, Inc (Threshold) is a biotechnology company focused on the discovery and development of drugs targeting the microenvironment of solid tumors as treatments for patients living with cancer. Its product candidates are designed to focus on the hypoxic microenvironment of tumors either by selective toxin activation in the case of its hypoxia activated prodrug (HAP) program, including TH-302, or utilizing the consequences of increased uptake of glucose in cancer cells relative to most normal cells. The Company's product candidate 2-deoxyglucose (2DG) and glufosfamide share certain structural characteristics with glucose but act instead as chemotherapeutic toxins when taken up by a cell.
BUY THIS DOCUMENT NOW PRICE: $24.95 100% MONEY BACK GUARANTEED
PARTNER Wright Investors' Service
Wright Investors' Service is an internationally recognized investment management and financial advisory firm headquartered in Milford, Connecticut. For more than 40 years, Wright has used well-defined and sophisticated investment strategies to help institutions, plan sponsors, bank trust departments, trust companies and individual investors achieve their financial objectives through a sensible approach to managing assets that balances risk and return.